German biotech company bitop AG announced that it has begun enrolling patients in a clinical trial of its Ectoin inhalation solution for the treatment of airway inflammation. In addition to the inhalation solution, bitop is also developing an Ectoin nasal spray and and a DPI. According to bitop, Ectoin is a naturally-occurring "cell protection molecule." Read the company’s press release.
Bitop initiates trial of Ectoin inhalation solution
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK